檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽
|
|
|
- Dana Garrison
- 7 years ago
- Views:
Transcription
1 * ( ) : : ; ; ; :R951.7 (712) :A : (2011) ResearchonOrphanDrugSalesModelofProfessionalPharmacyinU.S. XuYiWangYingxiaoandGongShiwei * (TongjiMedicalColegeHuazhong UniversityofScienceand TechnologyWuhan430030) ABSTRACT: Objective To explore Chinese orphan drug sales modelto promote orphan drug availability. Methods U.S.orphan drug sales modelofprofessionalpharmacy wasanalyzed bythe literatureresearchmethoddrawingonitssuccessfulexperiencemadetheselectionideafororphandrug salesmodeinchina.resultsinalusiontothesalescharacteristicsoforphandrugsuchasirregularlow demandhighphysicalandpsychologicalneedsmedicationhighpersonalizedmedicinetimelinessofdrug demandhighpricesandhighpurchasecosttheu.s.productioncirculationandenterprisesoforphan drugwereadoptdiferentmarketing methodstocommondrugssuchastheestablishmentofspecialized informationserviceplatformtosynchronizationofsalessalesdemonstrationsstafpromotionsservice promotionstargetingprofessionalsalesmailorderandpublicrelationsstrategiestargeted marketing. ConclusionIn ourcountryin each province or prefecture-levelcityto determinethe professional pharmacyandorphandrugproductionandreservesofthedirectorytotargetcustomerbaselocatedinthe rarepatientsdoctorsdrugmanufacturersinsurerstogethertoimproveorphandrugsaccessibility. KEY WORDS: professionalpharmacy;raredisease;salesmodel;orphandrug WHO WHO 5000 ~ % : ( ) : ; : ; shwgong@yahoo.com.cn
2 ; Diplomat Pharmacy US Oncology (US ; OncologyCare Advantage) [2] (specialtypharmacyprograms) ; [1] [6] IMS Health [7] %20089 ~ (specialtypharmacy) 2 (Specialty Pharmaceuticals) (FDA) DavidA.Blaser [2] : [8] P.L.Sauerwald [4] 8 5 : [3] ; ; ( ); ; 6000 ~ ; ; :(1) WalgreensCVS (2) (3) [4] [9] (PBM) PBM [5] CVS Caremark Ⅱ MedcoExpress Scripts UnitedHealth (United ( ) ( Health Prescription Solutions) Aetna (Aetna ) Specialty) Walgreens (Walgreens Specialty)
3 CVSCaremark United Health (Cimzia) (Humira) (Remicade) (Tysabri) (Pulmozyme) (Tobi) (Adagen) β- A(Fabrazyme) α1- (AAT)α1 (Aralast) (PKU) (BH4) Pompe/ Ⅱ VI(MPSVI) (Kuvan) (Kuvan) α- (Myozyme) (Naglazyme) 1 (HT-1) (Orfadin) (SBS) a-1 (Prolastin) (Ceredase) (Cerezyme) (Zavesca) (Zorbtive) Ⅱ ( ) (Elaprase) (Exjade) (MS) Ⅰ(MPS-I) dalfampridine(ampyra) β (Avonex) β -1b (Betaseron Extavia) (Copaxone) (Novantrone) β -1a (Rebif) (Tysabri) (Apokyn) (Adcirca) (Flolan) (Letairis) (Remodulin) (Revatio) (Tracleer) (Ventavis) (Aptivus) (Retrovir) AtriplaKaletra( )Truvada( ) (Aldurazyme) (Somavert) Ⅸ(Mononine) VI(NovoSeven) Ⅷ(Advate KogenateFS Xyntha) (VWD) / (Alphanate) ; ;Mail- ;
4 (Robert Lauterborn) 4P 4Cs (Customer) (Cost) (Convenience) (Communication) 4Cs [11] ; ; ; ( ) [7] 4Cs 4 4P 4P (patients) (physicians) (payers) (pharmaceuticalmanufacturers) 3 24h [2] PBM [10] [7] 3 [4] 24h ; ; ; ( ; ; ; ( ); ( ; ; ); / / / ); ; ; ; ; ; ; ; ;
5 ( ) : [1] 5 (4): (6): ; ; (6): ; [J] (2): [2] RowenaN.SchwartzKirbyJ.EngDeborah A.Frieze etal.nccn TaskForceReport:SpecialtyPharmacy [J]. National Comprehensive Cancer NetworkJuly [3] SuzanneSheley.RareDiseasesandOrphanDrugsLiftPhar- mainnovation [J].PharmaceuticalCommerce2010. [4] PamelaLeighSauerwald.ChangingtheChannel:Develop- mentsin US Specialty Pharmaceutical Distribution [J]. PharmaceuticalCommerce2009. [5] RitaShane.Managementofchronicdiseasesinthe21stcen- tury:theemergingroleofspecialtypharmacies [J].AmJ Health-SystPharm : [6] JamesA.Jorgenson.SpecialtyPharmacy:StatusandFuture Direction [J].TheAmericanJournalofPharmacyBenefits [7] BenComer.SpecialtyPharmaceuticals:ShiftingSpecialties [J].MedicalMarketingand Media2010. [8] DavidA.BlaserAndreaJ.LewtasMariaM.Ousterhout. Howto DefineSpecialtyPharmaceuticals-A SystematicRe- view [J]. The American Journalof Pharmacy Benefits [9] SeanD.Sulivan.ThePromiseofSpecialtyPharmaceuticals: AreThey WorththePrice[J].JournalofManagedCare Pharmacy (4)(Supplement):3-6. [10] SarahColin.SpecialtyPharmacy ManagementWilBecome MoreIntense [J]. Managed Care (10):20- [11] PennyBemus.BuildingAn AlternativeDistribution Model ForUltra-OrphanDisease [J].PharmaceuticalCommerce 檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽 ( 1234) [4].HPLC [J]. [J] (6): [5].HPLC [10]. [J] (1): [6]. [J] (4): [9] (2): [J] (8): [11]. [J]. [7] (4): HPLC [12].HPLC-UV-ELSD [J] (2): [8] [J] HPLC [J] (4): (11):
Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center
Specialty Pharmacy Business Plan July 8, 2013 Specialty Pharmaceuticals What are they? Biotech/gene-based therapy Require special handling Newer products oral or self- administered One third have REMS
Sector Analysis February 4, 2016
Sector Analysis Analysis of Orphan Drug Market There is significant interest among drug makers and investors alike to focus on the development of products for orphan indications. The reason is these drugs
The Basics of Pharmacy Benefits Management (PBM) 2009
The Basics of Pharmacy Benefits Management (PBM) 2009 Andrew Kingery Pharmacy Account Management Virginia CE Forum 2009 Course# 201719 Objectives & Introduction Provide basic components of a PBM Define
scriptsourcing THE NEXT 5 YEARS OF RX COSTS AND HOW THEY WILL IMPACT YOUR BOTTOM LINE ScriptSourcing Prescription Advocacy Services
scriptsourcing THE NEXT 5 YEARS OF RX COSTS AND HOW THEY WILL IMPACT YOUR BOTTOM LINE ScriptSourcing Prescription Advocacy Services Gary Becker, CEO Benefit Consultant, Risk Mitigation Expert, and Author
Specialty Pharmacy. Oncology
Specialty Pharmacy Oncology Background What are specialty drugs? Not an FDA designation No standard industry definition Categorized as: High cost (>$1,200 / month) Require special handling and administration
Inventory of Access and Prices of Orphan Drugs across Europe:
www.eurordis.org Inventory of Access and Prices of Orphan Drugs across Europe: A Collaborative Work between National Alliances on Rare Diseases & Eurordis Yann Le Cam Chief Executive Officer, EURORDIS
Retail Pharmacy Trends. Ed Escalante, VP/GM Edgar Cardona, VPS May 13, 2013 San Francisco, CA
Retail Pharmacy Trends Ed Escalante, VP/GM Edgar Cardona, VPS May 13, 2013 San Francisco, CA About this presentation Knowing Your Market Helps You Plan Ahead Understanding the latest retail pharmacy trends
REVISING SPECIALTY TIERS
WHITE PAPER REVISING SPECIALTY TIERS PROTECTING MEDICARE PART D BENEFICIARIES FROM BURDENSOME COST SHIFTING Gary G., Michigan Gary thought he had his financial assistance grant set up to cover his out-of-pocket
CONNECTICARE, INC. & AFFILIATES
CONNECTICARE, INC. & AFFILIATES INSERT PAGE FOR PRE-CERTIFICATION AND PRE- AUTHORIZATION LISTS UPDATE Applies to all ConnectiCare health plans, except the ConnectiCare Network USA-PPO Plan and as otherwise
RMIP Prescription Plan FAQ's
RMIP Prescription Plan FAQ's A new U.S. Pharmacy Benefit Manager has been selected for January 1, 2015 - CVS/caremark. 1) Why is the RMIP changing to CVS/caremark? The Express Scripts contract ends on
Agenda. Medicare Overview Medicare Part B Drug Coverage Medicare Part D: How to Find and Compare Medicare Part D Plans Summary Provider Contacts
2 Medicare Part D Agenda Medicare Overview Medicare Part B Drug Coverage Medicare Part D: Background Benefits of Medicare Part D Enrollment Coverage Specialty Medications Part D Costs How to Find and Compare
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
Can an administrative drug claims database be used to understand claimant drug utilization?
Can an administrative drug claims database be used to understand claimant drug utilization? By Elaine McKenzie, BSP, MBA, Consultant, TELUS Health Analytics Elaine McKenzie is a consultant who works with
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE August 20, 2015 SUBJECT EFFECTIVE DATE September 28, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER 99-15-08 BY Specialty Pharmacy Drug Program Pharmacy Services Leesa M. Allen, Deputy Secretary Office
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone Individuals, Families, States, Taxpayers All Face Higher Costs Due to Rising Drug Prices Prescription drugs are one of the major drivers
January 1, 2014. Participating Agencies
January 1, 2014 PA Participating Agencies For Active Employees, Retirees, Vestees and Dependent Survivors, Enrollees covered under Preferred List Provisions, their Dependents, COBRA enrollees and Young
Student Employee Health Plan (SEHP) for Graduate Student Employees
New York State Health Insurance Program Student Employee Health Plan (SEHP) for Graduate Student Employees January 1, 2009 For Graduate Student Employees and for their enrolled Dependents and for COBRA
ACTEMRA. Step Therapy Criteria HEALTH CHOICE EXCHANGE 2016 Effective Date: 01/01/2016. PRODUCT(s) AFFECTED ACTEMRA
ACTEMRA ACTEMRA Claim will pay automatically for Actemra if enrollee has a paid claim for at least a 1 days supply of Enbrel and Humira in the past 365 days. Otherwise, Actemra requires a step therapy
UPDATED INVESTOR PRESENTATION June 2015
UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans
SPECIALTY TREND MANAGEMENT
SPECIALTY TREND MANAGEMENT Table of Contents Specialty drives pharmacy trend... Chapter 1 Managing price, mix and utilization... Chapter 2 Expand preferred drug strategies... Chapter 3 Cost-effective site
Original Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
Overview of the Specialty Drug Trend
WHITE PAPER Overview of the Specialty Drug Trend Succeeding In The Rapidly Changing U.S. Specialty Market 1 Specialty drugs are prescribed to treat complex conditions such as cancer, HIV and inflammatory
Great-West s Drug Prior Authorization
Great-West s Drug Prior Authorization Great-West Life s prior authorization process is designed to provide an effective approach to managing claims for specific prescription drugs. Approval for coverage
Resources for the Primary Care Provider. Please print these out for reference
Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical
Medi-Cal Expansion, Mental Health Services and Changes to Medi-Cal Prior Authorization Requirements
REGULATORY DECEMBER 19, 2013 UPDATE 13-545 12 PAGES Medi-Cal Expansion, Mental Health Services and Changes to Medi-Cal Beginning January 1, 2014, Medi-Cal coverage is expanding under the Affordable Care
Kaiser Permanente s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting Use
Perspective Kaiser Permanente s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting Use A large integrated delivery system reports on its management of specialty pharmaceuticals.
Specialty Drug Program RX Benefit Member Guide
Specialty Drug Program RX Benefit Member Guide bcbsm.com Enrollment Form for Walgreens Specialty Pharmacy, LLC. How to place your initial order with Walgreens Specialty Pharmacy: 1) Print and complete
Effective: July 28, 2015. Arizona Prior Authorization Requirements Health Net Access, Inc.
Effective: July 28, 2015 Arizona Prior Authorization Requirements Health Net Access, Inc. The following services, procedures and equipment are subject to prior authorization requirements (unless noted
Pharmacy Benefit Managers: What we do
Pharmacy Benefit Managers: What we do Steve Boekenoogen, Pharm.D. Poulsbo, WA & San Diego CA Manager, Clinical Services & Integration MedImpact Healthcare Systems, Inc Dan Danielson, M.S., RPh. Lynnwood,
PATIENT / VISIT INFORMATION PATIENT INFORMATION
PATIENT / VISIT INFORMATION PATIENT INFORMATION Name of Patient: Date of Birth: Date of Visit: VISIT INFORMATION Please complete this form in its entirety, and present it to the registration desk when
Specialty drug trend
2 0 0 8 Specialty drug trend r e p o r t Specialty Pharmacy A n E x p r e s s S c r i p t s C o m p a n y Lead Authors Emily Cox, PhD, RPh Yakov Svirnovskiy, MA Chris Peterson, PharmD Aimee Tharaldson,
Provider Manual. This manual is to help you learn more about The Ohio State University s medical plans, administered by OSU Health Plan Inc.
2014 Provider Manual This manual is to help you learn more about The Ohio State University s medical plans, administered by OSU Health Plan Inc. We hope you find this information and the enclosed documents
Self-injectable, infused and oral specialty drugs 2014 Aetna Specialty CareRx SM Benefits Plan Drug List
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Self-injectable, infused and oral specialty drugs 2014 Aetna Specialty CareRx SM Benefits Plan Drug List 05.03.382.1
Specialty Pharmacy? Disclosure. Objectives Technician
Disclosure What s so SPECIAL about? I have no actual or potential conflict of interest in relation to this program/presentation. Michael DeCoske, PharmD, BCPS Associate Chief Pharmacy Officer Duke University
Prescription Drug Utilization and Cost Trends, 2009-2013
Agenda Item 7 Attachment 1 Prescription Drug Utilization and Cost Trends, 2009-2013 Pension and Health Benefits Committee October 14, 2014 Melissa Mantong, PharmD CalPERS Pharmacist Overview Trends in
Growth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
Winter 2013. Changing landscapes, pipeline products and plan sponsor impact
Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster
January 1, 2016 At A Glance. CSEA Civil Service Employees Association
January 1, 2016 At A Glance CSEA Civil Service Employees Association For Employees of the State of New York represented by Civil Service Employees Association (CSEA) and for their enrolled Dependents;
Medical School for Actuaries. June 12, 2013. Baltimore, Maryland
Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments
What is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
At a Glance. NewYork State Health Insurance Program. January 1, 2009. Participating Employers
January 1, 2009 The Empire Plan is a comprehensive health insurance program for NewYork s public employees and their families.the plan has four main parts: At a Glance NewYork State Health Insurance Program
Prescription Drug Benefit Description
Prescription Drug Benefit Description Herein called Description Prescription Drug Program For State of Kansas Employees Health Plan This booklet describes the Prescription Drug benefits available through
Three years ago, the mantra for
MANAGING MS: Trends, Issues, and Perspectives The entry of oral medications for multiple sclerosis into the marketplace and the high cost of biologic drugs are presenting new challenges for stakeholders.
AUBAGIO. Step Therapy Criteria Health Choice Generations Formulary ID: 15179 Version 19 Effective Date: 11/1/2015. PRODUCT(s) AFFECTED AUBAGIO
AUBAGIO AUBAGIO Claim will pay automatically for AUBAGIO if enrollee has a paid claim for at least a 1 days supply of COPAXONE, REBIF, TYSABRI, BETASERON OR EXTAVIA in the past 365 days. Otherwise, AUBAGIO
INPATIENT SERVICES Commercial Medicare. Notification required only, as soon as possible, but no later than 24 hours
Effective: January 1, 2016 Arizona Prior Authorization Requirements HMO (including CommunityCare HMO) Point-of-Service (POS) PPO Advantage (MA) HMO The following services, procedures or equipment are subject
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents
Multiple Sclerosis Treatment Experience Questionnaire (MSTEQ)
Multiple Sclerosis Treatment Experience Questionnaire (MSTEQ) Name: Today s date (mm/dd/yy): It is important that you take your as prescribed by your physician. However, from to you may find it difficult
drug trend and therapy class review CuraScript Specialty Pharmacy Management Guide & Trend Report
drug trend and therapy class review CuraScript Specialty Pharmacy Management Guide & Trend Report Drug Trend and Therapy Class Review The growth of specialty drugs continues to outpace the traditional
22 Medicare Provider Manual
22 Medicare Provider Manual Table of Contents Title Page Introduction 2 Important Contact Information 4 Member Eligibility & Plan Design 5 ID card sample 8 Provider Reconsideration Process 9 Member Grievance
Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with
Study Support Materials Cover Sheet
Study Support Materials Cover Sheet Document Title ESCALATE Patient Brochure Intended Audience This brochure is designed to be given to potentially eligible patients as a take-home summary of key information
PULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan
The MS Disease- Modifying Drugs. Gener al information
The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please
How to S.E.A.R.C.H. SM for the Right MS Therapy For You!
How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration
PBM Revenue Generation Secrets HEALTHCARE ANALYTICS
PBM Revenue Generation Secrets HEALTHCARE ANALYTICS TODAY S AGENDA Brief background on the Prescription Benefits Manager (PBM) marketplace Basic Components of a PBM Contract How PBMs are exploiting contract
Specialty Pharmacy: Understanding the Market and Solution. Your Goals. Presented by Chris Brown November 2009
Specialty Pharmacy: Understanding the Market and Solution Presented by Chris Brown November 2009 Your Goals What What is a Specialty is a specialty Medication? medication? Specialty drugs are injectable,
Here for you. Here for your health.
Here for you. Here for your health. A guide to your plan Contact information This guide to your plan can help you make the most of your health care and Assurant Health s Customer Care Center can do the
April 30, 2009. The Honorable Edward M. Kennedy Chairman Committee on Health, Education, Labor, and Pensions United States Senate
United States Government Accountability Office Washington, DC 20548 April 30, 2009 The Honorable Edward M. Kennedy Chairman Committee on Health, Education, Labor, and Pensions United States Senate Subject:
Aubagio. AgeWell Drugs that Require Step Therapy Last Updated: 08/08/2014. Products Affected. Details AUBAGIO TAB 14MG AUBAGIO TAB 7MG
Aubagio AUBAGIO TAB 14MG AUBAGIO TAB 7MG Claim will pay automatically for AUBAGIO if enrollee has a paid claim for at least a 1 days supply of COPAXONE, REBIF, TYSABRI, BETASERON OR EXTAVIA in the past
1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
Committee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
If you have any questions about GLG Research Studies or you want to commission a Custom Report, please contact Sam Jacobs sjacobs@glgroup.com.
GLG Research Study Tysabri for Multiple Sclerosis Views from 245 Neurologists A GLG Research Study of 245 US-based neurologists about their opinion of Tysabri for the treatment of multiple sclerosis, given
LIVING WELL An Integrative Approach to Wellness with MS Member Application
LIVING WELL An Integrative Approach to Wellness with MS Member Application Name: Date: Address: City: State: Zip: Phone: Home Work Cell E-mail address: Fax: Gender: Male Female Handedness: Left Right Both
TrueView Underwriting SM
Quick Reference Guide I Long Term Care Insurance TrueView Underwriting SM Quick Reference Guide Underwritten by Genworth Life Insurance Company and in New York by Genworth Life Insurance Company of New
Nathalie Gingras, FSA, FICA, CRHA Jonathan Bohm, FSA, FICA
Nathalie Gingras, FSA, FICA, CRHA Jonathan Bohm, FSA, FICA June 19, 2014 _ On Today s Agenda Objective for the day Context White Paper : A Solution for Private Drug Plans Catastrophic Drug Insurance Questions
The Impact of Medicare Part D on Pharmacy Benefit Managers
The Impact of Medicare Part D on Pharmacy Benefit Managers Actuaries Club of the Southwest and Southeastern Actuaries Conference Joint Annual Meeting November 17, 2006 Troy M. Filipek, FSA, MAAA Actuary
Information About Medicines for Multiple Sclerosis
Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain
Insight. Drug Class. Background, new developments, key strategies. Introduction. Faulty signals. 400,000 patients in the US 1
Drug Class Insight Multiple Sclerosis Background, new developments, key strategies Introduction 400,000 patients in the US 1 Most people diagnosed between age 20 50 2 2-3x more women than men get MS 2
Equipment Distribution Program Application 375 Kings Highway North, Cherry Hill, NJ 08034 (800) 532-7667 Web: www.mymsaa.org
Equipment Distribution Program Application 375 Kings Highway North, Cherry Hill, NJ 08034 (800) 532-7667 Web: www.mymsaa.org Application for Safety, Mobility, and Daily Living Products Individuals with
The rising cost of prescription drugs to treat multiple sclerosis in upstate New York
T H E F A C T S A B O U T The rising cost of prescription drugs to treat multiple sclerosis in upstate New York Per-person mean annual prescription drug cost to treat multiple sclerosis Annual drug cost
PHARMACEUTICAL, BIOTECHNOLOGY AND MEDICAL DEVICE MANUFACTURERS SELECT PUBLIC INVESTIGATIONS
PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE MANUFACTURERS Current as of July 2015 attorney advertisement 3175 Hanover Street, Palo Alto, CA 94304 The content of this packet is an introduction to
STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12
STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What
Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)
Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the
N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative
Actimmune Amlodipine Androderm Anticonvulsant Antidepressants Antineoplastics Antipsychotics Arcalyst Butalbital Colony Stimulating Factors ESRD Therapy Actimmune Norvasc Androderm Banzel Keppra Mysoline
Specialty Pharmacy Definition
Isn t All of Special? Developing Services Presented to: 2015 ICHP Annual Meeting Presented on: September 10, 2015 Presented by: Lana Gerzenshtein, Pharm.D., BCPS The speaker has no conflicts of interest
10/10/2008. Orphan drugs. Orphan drugs. Legislation Prevalence and evolution Slicing Cost. Raw materials Rare diseases: capita selecta Conclusions
Orphan drugs Orphan drugs Definitions Definitions Legislation Prevalence and evolution Slicing Cost Dispensing Raw materials Rare diseases: capita selecta Conclusions 1 Definition: Orphan disease The term
NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT
NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT Please complete the Fax Cover Sheet and Service Request Form, and fax all pages to the number specified below. Dear Health Care Professional: The Novartis
Disease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
Pharmacy Benefit Managers
Pharmacy Benefit Managers And the need for fair and reasonable standards over the practice of auditing pharmacies SB 175 Establishes Procedures & Guidelines for the Auditing of Pharmacy Records & Requires
Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation
Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust
全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report
/wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天
Contents: Attachments: Volume 12.12 Rochester Region December 2006. Visit our Web site at excellusbcbs.com
Volume 12.12 Rochester Region December 2006 Contents: Updated Provider Manuals on Web, p.2 Patterns Review Retires, p.2 Complete All Fields for Research/Claim Adjustment, p2 Sharing NPI Info, p.3 Healthy
The Pharma/Payer Relationship Strategies for the Next Two Years
Health & Life Sciences The Pharma/Payer Relationship Strategies for the Next Two Years by Mark Mozeson Nipon Das, M.D. The power to determine what pharmaceutical products are bought and at what price has
An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit
An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit March 2014 PREPARED BY Brenda Motheral, MBA, PhD President Corey Belken, PharmD Vice President Artemetrx Specialty Drug Solutions
Relapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
SammyJo s MS-LDN Timeline
SammyJo s MS-LDN Timeline Better 1 Stop all other meds 4/4 2 EDSS Disability Scale 3 3 3.5 3.5 3.5 3.5 4 4 4 4 4.5 5 5_ 6 7 8 Start LDN 2/4 6.5 7 9 Worse 1 Steroids Copaxone Novan trone Avonex Steroid
Strategic Issues in Managing the Specialty Pharmacy Benefit. Tim Watson, PharmD, MBA
Strategic Issues in Managing the Specialty Pharmacy Benefit Tim Watson, PharmD, MBA Strategic Issues in Specialty Pharmacy Management Specialty pharmacy goals: Provide a reliable source for hard-to-find
Towards a New Model of Delivery of Care
Towards a New Model of Delivery of Care What can we do Different to Provide Better Delivery of Care? Algis Jovaisas, MD,FRCPC Division of Rheumatology University of Ottawa Current Modelsurrent Private
FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM
FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM ABBVIE EMPLOYEES WANT TO KNOW What s New in 2015? AbbVie is making changes in its pharmacy benefit program to ensure our medical
Is it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
this 7^ day of September 2014 by Randall S. Gregg Special Deputy Director
r STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v File No. 143525-001 Health Alliance Plan of Michigan,
Multiple Sclerosis Drug Discoveries - What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally
Multiple Sclerosis Treatments: World Market Outlook to 2011
Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating
NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT
NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT Please complete the Fax Cover Sheet and Service Request Form, and fax all pages to the number specified below. Dear Health Care Professional: The Novartis
Pharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Pulmonary Arterial Hypertensive (PAH) agents Rx.01.83 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
4Precertification. and Referrals. Precertification...59 Referrals (Gated Plans Only)...73
4Precertification and Referrals Precertification.....................59 Referrals (Gated Plans Only)............73 Section 4 Precertification and Referrals 58 www.oxfordhealth.com Precertification and
Disease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
Marlene E. Haffner, MD, MPH, RADM USPHS, Director
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Orphan Products Development Memorandum DATE: March 7, 2002 FROM: SUBJECT: TO: Marlene E. Haffner, MD, MPH, RADM
Prescription Drug Summary Plan Description
Prescription Drug Summary Plan Description About This Summary Plan Description (SPD) The Prescription Drug Program is a component program in the Tenet Employee Benefit Plan (TEBP). The TEBP is a comprehensive